TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32438828

Group type: EXPERIMENTAL
Intervention: MSTEP© (tailored exercise programme)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Guideline (general exercise guidelines)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: MSTEP©
Number of subjects: 137

Group type: COMPARATOR
Intervention: Guideline
Number of subjects: 137
Study: 35086692

Group type: EXPERIMENTAL
Intervention: KVD900 600 mg tablet under fasted conditions
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: KVD900 600 mg tablet
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: KVD900 600 mg dose
Number of subjects: 98

Group type: COMPARATOR
Intervention: KVD900 (various doses)
Number of subjects: 98
Study: 33784967

Group type: EXPERIMENTAL
Intervention: GP research networks as a recruitment strategy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cold calls as a recruitment strategy
Number of subjects: 130
Study: 32865465

Group type: EXPERIMENTAL
Intervention: PBM applied with 30 J per area (PBM1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBM applied with 120 J per area (PBM2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBM applied with 180 J per area (PBM3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study: 35461287

Group type: EXPERIMENTAL
Intervention: Standard measles vaccine
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5400
Study: 32107938

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (high-intensity statins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or usual care
Number of subjects: 0
Study: 34791805

Group type: EXPERIMENTAL
Intervention: 3 mg PEG rhG‐CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (5 μg/kg rhG‐CSF administered when ANC reached grade 3)
Number of subjects: 0
Study: 32098573

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based neoadjuvant chemotherapy (NACT) administered to 45 patients for a median of 8 weeks prior to surgical resection.
Number of subjects: 92

Group type: COMPARATOR
Intervention: NACT group (short interval)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Long-interval and no NACT groups
Number of subjects: 92
Study: 33560775

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE) (25 min at 45% PPEAK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) (8 × 60 s at 70% PPEAK)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-Exercise Control (REST)
Number of subjects: 10
Study: 32639470

Group type: EXPERIMENTAL
Intervention: PICU Supports
Number of subjects: 382

Group type: COMPARATOR
Intervention: Brochure
Number of subjects: 382
Study: 35667770

Group type: EXPERIMENTAL
Intervention: 110% high frequency (HF) rTMS
Number of subjects: 38

Group type: COMPARATOR
Intervention: 70% low frequency (LF) rTMS
Number of subjects: 38
Study: 33234156

Group type: EXPERIMENTAL
Intervention: Negative viscosity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive viscosity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breakthrough force
Number of subjects: 0
Study: 34426738

Group type: EXPERIMENTAL
Intervention: Active cathodal tDCS of the primary motor cortex of the unaffected hemisphere (ctDCSM1UH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 30
Study: 33940235

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg−1 of low dose rocuronium
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-NMBA (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 33374218

Group type: EXPERIMENTAL
Intervention: Octanoate-rich MCTs (C8R)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Decanoate-rich MCTs (C10R)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (C8R and C10R)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Carbohydrate (control)
Number of subjects: 3
Study: 32384953

Group type: EXPERIMENTAL
Intervention: nAg‐NPs (≥0.5 g/mL)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: nAg‐NPs (0.05 g/mL)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: nAg‐NPs (5 g/mL)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: nAg‐NPs
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nursing management modes
Number of subjects: 88
Study: 35322167

Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercises
Number of subjects: 24
Study: 32979978

Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated to a maximum dose of 2700 mg daily)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 35697547

Group type: EXPERIMENTAL
Intervention: Intraoperative lidocaine infusion (continuous infusion of 2 mg kg‐1 h‐1 after 1.5 mg kg‐1 bolus at induction of anaesthesia)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 563
Study: 34215238

Group type: EXPERIMENTAL
Intervention: Peking University First Hospital Score (PUFHS)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 272
Study: 33225651

Group type: EXPERIMENTAL
Intervention: Reverse breech extraction (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hand push method (Group B)
Number of subjects: 110
Study: 36473006

Group type: EXPERIMENTAL
Intervention: MyPinkMom intervention program (six infographic video clips)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine counseling on anemia in pregnancy)
Number of subjects: 120
Study: 32795589

Group type: EXPERIMENTAL
Intervention: Methylation of MSI2
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Differentially methylated positions (DMPs) associated with atopy
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Changes in MSI2 expression and methylation
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Differentially methylated positions (DMPs) associated with tissue eosinophilia
Number of subjects: 291
Study: 32385495

Group type: EXPERIMENTAL
Intervention: Experimental treatment (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active reference treatment (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34972076

Group type: EXPERIMENTAL
Intervention: Triple-LED/loupe device
Number of subjects: 26

Group type: COMPARATOR
Intervention: BLUE400 system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of triple-LED/loupe device to BLUE400
Number of subjects: 26
Study: 33932179

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis patients (case group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (patients without allergic rhinitis)
Number of subjects: 250
Study: 32917288

Group type: EXPERIMENTAL
Intervention: Mistletoe extract (0.01 to 20 mg subcutaneously three times per week for 9 months)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo (subcutaneously)
Number of subjects: 290
Study: 32444433

Group type: EXPERIMENTAL
Intervention: InSpace balloon (Stryker, USA) with arthroscopic debridement
Number of subjects: 221

Group type: COMPARATOR
Intervention: Arthroscopic debridement alone
Number of subjects: 221
Study: 33914664

Group type: EXPERIMENTAL
Intervention: BFR20
Number of subjects: 10

Group type: COMPARATOR
Intervention: FF70
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FF20
Number of subjects: 10

Group type: COMPARATOR
Intervention: FF20WM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 10
Study: 33109233

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant lapatinib, trastuzumab, or their combination plus paclitaxel
Number of subjects: 454
Study: 36047598

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous ferric carboxymaltose
Number of subjects: 278

Group type: COMPARATOR
Intervention: 1000 mg intravenous ferric carboxymaltose
Number of subjects: 278
Study: 33762190

Group type: EXPERIMENTAL
Intervention: MgSO4 50mgkg‐1 for 15 minutes followed by 15 mgkg‐1h‐1 until the end of the surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups received 100μg of ITM
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups received dipyrone+ketoprofen intraoperatively and postoperatively, and dexamethasone intraoperatively only
Number of subjects: 86
Study: 32334548

Group type: EXPERIMENTAL
Intervention: mDCF plus atezolizumab (800 mg every 2 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: mDCF
Number of subjects: 99
Study: 35620476

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) delivered at Zusanli (ST36) and Neiguan (PC6) acupoints 24 hours before surgery.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA) group.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group.
Number of subjects: 80
Study: 33129363

Group type: EXPERIMENTAL
Intervention: Favipiravir and Hydroxychloroquine combination
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 472
Study: 35751913

Group type: EXPERIMENTAL
Intervention: Six-session socio-behavioral health intervention utilizing sociodrama
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34063191

Group type: EXPERIMENTAL
Intervention: Whole grain rye bread (WGR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Whole grain wheat bread (WGW)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Refined wheat bread (WW)
Number of subjects: 9
Study: 34610151

Group type: EXPERIMENTAL
Intervention: Adjunctive Er:YAG laser (ERL) in non-surgical periodontal therapy (NSPT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment in non-surgical periodontal therapy (NSPT)
Number of subjects: 22
Study: 33752127

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 35587078

Group type: EXPERIMENTAL
Intervention: Laser biostimulation (LB) and low-calorie diet (LCD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-calorie diet (LCD) alone
Number of subjects: 66
Study: 33352004

Group type: EXPERIMENTAL
Intervention: Washing without water method
Number of subjects: 97

Group type: COMPARATOR
Intervention: Water and soap method
Number of subjects: 97
Study: 33496530

Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with extra-virgin olive oil or nuts
Number of subjects: 2188

Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with extra-virgin olive oil
Number of subjects: 2188

Group type: COMPARATOR
Intervention: Antihypertensive therapy at baseline
Number of subjects: 2188
Study: 35303516

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) enriched meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fat (FAT) enriched meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Protein (PRO) enriched meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 32
Study: 34836152

Group type: EXPERIMENTAL
Intervention: Common Bean Baked Snack (CBBS) consumption (32 g for four weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no CBBS consumption)
Number of subjects: 20
Study: 32033718

Group type: EXPERIMENTAL
Intervention: 17β‐E2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36089442

Group type: EXPERIMENTAL
Intervention: 50 g of force
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 g of force
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 g or 150 g of force
Number of subjects: 0
Study: 32173640

Group type: EXPERIMENTAL
Intervention: Simvastatin combined with exercise training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 180
Study: 35405603

Group type: EXPERIMENTAL
Intervention: Probiotic kefir (180 mL/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unfermented milk
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Probiotic kefir
Number of subjects: 62

Group type: COMPARATOR
Intervention: Probiotic kefir and unfermented milk
Number of subjects: 62
Study: 32621587

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment regimens (three or four times daily)
Number of subjects: 24
Study: 35803621

Group type: EXPERIMENTAL
Intervention: Awake prone positioning plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 32152811

Group type: EXPERIMENTAL
Intervention: Tagging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Feature Tracking (FT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tissue Tracking (TT)
Number of subjects: 20
Study: 34269632

Group type: EXPERIMENTAL
Intervention: Interventions designed to enhance treatment engagement
Number of subjects: 52
Study: 34011110

Group type: EXPERIMENTAL
Intervention: Complete social and family support
Number of subjects: 70

Group type: COMPARATOR
Intervention: Basic treatment only (Control)
Number of subjects: 70
Study: 32749491

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d of cholecalciferol)
Number of subjects: 18353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18353
Study: 33579690

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 34033171

Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35428817

Group type: EXPERIMENTAL
Intervention: Midazolam (MID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both MID and DEX
Number of subjects: 12
Study: 32458091

Group type: EXPERIMENTAL
Intervention: EF training
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 85
Study: 32149378

Group type: EXPERIMENTAL
Intervention: Sexual skills training program
Number of subjects: 70
Study: 36013490

Group type: EXPERIMENTAL
Intervention: Spinal orthopedic brace, acute use 24 h/day (n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spinal orthopedic brace, acute use between 15-18 h/day with specific rehabilitation exercise protocol for six months (n = 23)
Number of subjects: 45
Study: 616497335

Group type: EXPERIMENTAL
Intervention: Nursing intervention on the basis of conventional nursing care for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 80
Study: 35080497

Group type: EXPERIMENTAL
Intervention: PA-first group (4 weeks of PA followed by 4 weeks of FVC intervention)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: FVC-first group (4 weeks of FVC followed by 4 weeks of PA intervention)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group (8 weeks of placebo treatment unrelated to PA and FVC)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: FVC-first group
Number of subjects: 552
Study: 32159187

Group type: EXPERIMENTAL
Intervention: Resistant starch enriched cookies (16 g of RS per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo cookies
Number of subjects: 26
Study: 34670725

Group type: EXPERIMENTAL
Intervention: Handheld ultrasound device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional palpation
Number of subjects: 40
Study: 34391303

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 30
Study: 32107275

Group type: EXPERIMENTAL
Intervention: iRECIST
Number of subjects: 4751

Group type: COMPARATOR
Intervention: RECIST V.1.1
Number of subjects: 4751

Group type: EXPERIMENTAL
Intervention: iPFS
Number of subjects: 4751

Group type: EXPERIMENTAL
Intervention: PFS
Number of subjects: 4751
Study: 35428296

Group type: COMPARATOR
Intervention: Control group of the cluster randomised trial
Number of subjects: 301
Study: 32751204

Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional training (TRAD-G)
Number of subjects: 0
Study: 36297014

Group type: EXPERIMENTAL
Intervention: BCAAs (0.17 g/kg BCAAs + 0.17 g/kg glucose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.34 g/kg glucose)
Number of subjects: 0
Study: 34714820

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination at 28-day interval
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination at 56-day interval
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination at 84-day interval
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination after 1 year
Number of subjects: 810

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination in HIV-infected adults at 28-day interval
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination in HIV-infected adults at 56-day interval
Number of subjects: 810
Study: 35753286

Group type: EXPERIMENTAL
Intervention: Handout + video condition (8-module video intervention and detailed handout)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Handout condition (detailed handout only)
Number of subjects: 156
Study: 33196833

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35624201

Group type: EXPERIMENTAL
Intervention: M1 tDCS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 34447267

Group type: EXPERIMENTAL
Intervention: Celecoxib oral solution (120 mg, 4.8 mL)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 35671039

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32816151

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 107847

Group type: COMPARATOR
Intervention: Oral bisphosphonates
Number of subjects: 107847
Study: 35679357

Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 33127408

Group type: EXPERIMENTAL
Intervention: VATS left upper lobectomy
Number of subjects: 30
Study: 32891292

Group type: EXPERIMENTAL
Intervention: Music therapy integrated with family recollection (15 minutes, twice a day for 6 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 60
Study: 35723002

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan at $10/month
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan at $50/month
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan at $100/month
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Cost-primed group
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Not cost-primed group
Number of subjects: 1013
Study: 33214331

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 372

Group type: COMPARATOR
Intervention: NCPAP/NIPPV
Number of subjects: 372
Study: 33544989

Group type: EXPERIMENTAL
Intervention: 38%‐SDF + potassium iodide (KI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30%‐SDF
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2%‐CHX
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 33265920

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acyclovir (750 mg/m2 intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acyclovir (1600 mg per day orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acyclovir (250 mg/m2 per day intravenously)
Number of subjects: 16
Study: 36115256

Group type: EXPERIMENTAL
Intervention: Somatostatin analogue therapy (SSA)
Number of subjects: 68
Study: 33630460

Group type: EXPERIMENTAL
Intervention: Exposure to art
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study: 32521876

Group type: EXPERIMENTAL
Intervention: Group A: 13x3 Gy hypofractionated radiotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Group B: 2x8.5 Gy and one fraction of 6 Gy hypofractionated radiotherapy
Number of subjects: 29
Study: 35015806

Group type: EXPERIMENTAL
Intervention: High-protein yogurt (10 g protein/100 g)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal-protein yogurt (3.5 g protein/100 g)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 µg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (no vitamin D)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-protein yogurt
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal-protein yogurt
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-protein yogurt and vitamin D
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Normal-protein yogurt and vitamin D
Number of subjects: 200
Study: 33500291

Group type: EXPERIMENTAL
Intervention: Educational video on endoscopic extraperitoneal hernia repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mock video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital version of informed consent brochure
Number of subjects: 0
Study: 33368338

Group type: EXPERIMENTAL
Intervention: High-dose valaciclovir (900 mg, three times daily for 10 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low-dose valaciclovir (300 mg, two times daily for 10 days)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: High-dose valaciclovir
Number of subjects: 214